acib is leading a multi-disciplinary approach combining wet-lab human DLBCL patient-derived co-culture experiments with next generation sequencing and sophisticated bioinformatic analyses. The aim is to i) test for the best combinational therapy options ex vivo and ii) to discover transcriptional and immunological signatures characterizing patients as candidates for targeted therapies. This approach towards precision oncology will allow a personalized selection of treatment options for each patient and offer important considerations for the design of novel treatments.
acib has ample expertise in providing R&D services to various companies – check also our other project offers
acib offers selective fructose depletion with specific magnetic adsorbent materials. Different fructose-affine materials will be used and different magnetic separation methods can be tested for optimal performance. Fructose will be imprinted into polymers (MIP) to produce polymers that can selectively and reversibly bind fructose. This polymerisation will take place around magnetic supports, thus immobilising the affine polymer and establishing the possibility for magnetic separation. The juice/must and the magnetic MIPs are mixed and then the fructose molecules bound to the magnetic materials are magnetically extracted from the must. The fructose can then be eluted. The particle system can be used several times. The processes are supposed to be gentler and more cost-effective than existing systems from a traditional coupling of ultra- and nanofiltration processes. The advantage of magnetic separation lies in the higher selectivity. It is worth noting that the extracted fructose can be sold/used further e.g. as sweetener for other products.